Related Experiment Video
Updated: Jun 9, 2026
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
Anti-Obesity Pharmacotherapy and Emerging Multimodal Interventions for Obstructive Sleep Apnea
Anish Preshy1, Cornelius J Fernandez2, Mohammad Hamid Nedai3
1Department of Respiratory and Sleep Medicine Gold Coast University Hospital Gold Coast Queensland Australia.
Chronic Diseases and Translational Medicine
|June 8, 2026
Summary
Obstructive sleep apnea (OSA) management is shifting towards integrated obesity treatments. Weight loss interventions, including bariatric surgery and new pharmacotherapies like Tirzepatide, improve apnea-hypopnoea index (AHI) and offer alternatives to CPAP.
Area of Science:
- Sleep Medicine
- Endocrinology
- Cardiovascular Medicine
Background:
- Obstructive sleep apnea (OSA) is a global health crisis linked to obesity and cardiovascular issues.
- Continuous positive airway pressure (CPAP) is standard but doesn't address obesity's root cause.
- Weight loss is a key modifiable factor for OSA improvement.
Purpose of the Study:
- To review surgical, endoscopic, and pharmacological obesity interventions for OSA.
- To propose an individualized treatment framework integrating weight management with OSA therapies.
- To analyze the impact of new weight-loss agents on OSA management.
Main Methods:
- Literature review of surgical, endoscopic, and pharmacological interventions for obesity and OSA.
- Analysis of weight loss outcomes and apnea-hypopnoea index (AHI) reductions.
- Framework proposal for integrated, phenotype-tailored OSA and obesity care.
Main Results:
- Bariatric interventions yield 25-35% weight loss and 50-75% OSA remission.
- Incretin-based therapies like Tirzepatide achieve 10-22% weight loss and significant AHI reduction.
- New pharmacotherapies offer substantial weight loss and AHI improvements for OSA patients.
Conclusions:
- Obesity management is crucial for OSA treatment, complementing CPAP.
- Integrated strategies combining pharmacotherapy, lifestyle changes, and surgery are reshaping OSA care.
- Individualized treatment plans tailored to disease phenotypes are essential for optimal outcomes.
Related Concept Videos
01:21Sleep Apnea
Sleep apnea is a condition where breathing stops intermittently during sleep, often leading to significant health issues. Each episode can last from 10 to 20 seconds or more and is frequently accompanied by a brief arousal from sleep. This disturbance, largely unnoticed by the individual, can lead to severe daytime fatigue. Commonly, individuals seek help after being informed by their partners about loud snoring and noticeable breathing pauses during sleep.
The condition is more prevalent among...
The condition is more prevalent among...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:19Management of Insomnia
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...